title: Ustekinumab for Resistant Pediatric Crohn Disease.
authors.affiliation: *Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel †Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Sackler Faculty of Medicine, Tel-Aviv University, Israel.
authors.forename: Firas
authors.initials: F
authors.lastname: Rinawi
authors.forename: Yoram
authors.initials: Y
authors.lastname: Rosenbach
authors.forename: Amit
authors.initials: A
authors.lastname: Assa
authors.forename: Raanan
authors.initials: R
authors.lastname: Shamir
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy* / Q000503:physiopathology; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D018432:Drug Resistance, Multiple; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006130:Growth Disorders / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D060828:Induction Chemotherapy / Q000009:adverse effects; D007279:Injections, Subcutaneous; D060046:Maintenance Chemotherapy; D008297:Male; D015122:Mercaptopurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D012074:Remission Induction; D000069549:Ustekinumab / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; C488629:azathiopurine; D015122:Mercaptopurine; D000069549:Ustekinumab